CLINICAL TRIALS PROFILE FOR SOLUPREP S

All Clinical Trials for SOLUPREP S

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02447497 ↗	In Vivo Patient Preoperative Skin Prep Persistence	Completed	3M	Phase 2	2015-03-01	The objective of the study is to demonstrate persistence of the CHG/IPA Prep on skin flora of the abdominal and inguinal regions of human subjects.
NCT03859908 ↗	Comparison of Two Preoperative Antiseptic Solutions Alcohol Based in Abdominal Elective Surgeries	Unknown status	Maria-Virginia Rodriguez Funes	Phase 4	2019-04-05	Pragmatic randomized clinical trial comparing Iodine Povacrylex based on alcohol to Chlorhexidine also based on alcohol in efficacy and security to diminish frequency of surgical site infections in major abdominal elective clean contaminated wounds. Will be held in a third level university, high volume national public hospital in San Salvador, El Salvador.
NCT03859908 ↗	Comparison of Two Preoperative Antiseptic Solutions Alcohol Based in Abdominal Elective Surgeries	Unknown status	Universidad de El Salvador	Phase 4	2019-04-05	Pragmatic randomized clinical trial comparing Iodine Povacrylex based on alcohol to Chlorhexidine also based on alcohol in efficacy and security to diminish frequency of surgical site infections in major abdominal elective clean contaminated wounds. Will be held in a third level university, high volume national public hospital in San Salvador, El Salvador.
NCT04756154 ↗	Efficacy Study of Patient Preoperative Preps In-vivo	Recruiting	3M	Phase 3	2020-07-06	The purpose of this study is to determine the antimicrobial efficacy of an investigational CHG/IPA prep on skin flora of the inguinal regions of human subjects.

Clinical Trial Conditions for SOLUPREP S

Condition Name

Condition Name for SOLUPREP S
Intervention	Trials
Surgical Skin Preparation	1
Bacterial Recovery of Skin Flora Post-Product Application	1
Shoulder Pain	1
Surgical Site Infection	1

Condition MeSH

Condition MeSH for SOLUPREP S
Intervention	Trials
Shoulder Pain	1
Dilatation, Pathologic	1
Surgical Wound Infection	1

Clinical Trial Locations for SOLUPREP S

Trials by Country

Trials by Country for SOLUPREP S
Location	Trials
United States	2
Canada	1
El Salvador	1

Trials by US State

Trials by US State for SOLUPREP S
Location	Trials
Virginia	2

Clinical Trial Progress for SOLUPREP S

Clinical Trial Phase

Clinical Trial Phase for SOLUPREP S
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for SOLUPREP S
Clinical Trial Phase	Trials
Recruiting	1
Unknown status	1
Completed	1

Clinical Trial Sponsors for SOLUPREP S

Sponsor Name

Sponsor Name for SOLUPREP S
Sponsor	Trials
3M	2
Centre for Interdisciplinary Research in Rehabilitation of Greater Montreal	1
Fédération des médecins résidents du Québec	1

Sponsor Type

Sponsor Type for SOLUPREP S
Sponsor	Trials
Other	5
Industry	2

Last updated: May 1, 2026

Clinical Trials Update and Market Analysis for SOLUPREP S

What is SOLUPREP S and where is it in clinical development?

Insufficient information is available in the provided context to produce a complete and accurate clinical-trials update and market projection for “SOLUPREP S.”

What clinical trials exist, and what are their endpoints and timelines?

No trial registry identifiers, sponsor details, indication, trial phase, enrollment status, or published results are present in the provided context.

What is the market size, pricing, and forecast for SOLUPREP S?

No jurisdictional market data, indication, target population, dosing regimen, channel mix, or pricing benchmarks are present in the provided context.

What is the competitive landscape and how does SOLUPREP S differentiate?

No comparative product set, mechanism of action, formulation attributes, safety profile, or claimed clinical differentiators are present in the provided context.

What is the projected revenue path (global and by region)?

No sales assumptions (launch date, adoption curve, persistence, coverage, reimbursement, or hurdle rates) and no comparable launch history are present in the provided context.

Key Takeaways

• A complete clinical-trials update for SOLUPREP S cannot be generated from the provided information.
• A defensible market analysis and forecast cannot be produced without indication, development status, pricing, and competitive context tied to verifiable sources.

FAQs

1. Is SOLUPREP S approved in any market?
   Not determinable from the provided context.

2. Which clinical trial phases has SOLUPREP S completed?
   Not determinable from the provided context.

3. What endpoints define efficacy and safety for SOLUPREP S?
   Not determinable from the provided context.

4. What is the expected launch timeline and adoption rate?
   Not determinable from the provided context.

5. How does SOLUPREP S compare to existing therapies?
   Not determinable from the provided context.